A detailed history of Graham Capital Management, L.P. transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 31,517 shares of TSVT stock, worth $148,445. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,517
Previous 12,309 156.05%
Holding current value
$148,445
Previous $65,000 86.15%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.6 - $5.79 $69,148 - $111,214
19,208 Added 156.05%
31,517 $121,000
Q1 2024

May 15, 2024

BUY
$3.09 - $6.0 $38,034 - $73,854
12,309 New
12,309 $65,000
Q3 2023

Nov 22, 2023

BUY
$3.14 - $11.2 $157,521 - $561,859
50,166 Added 195.01%
75,891 $297,000
Q2 2023

Aug 14, 2023

BUY
$8.45 - $12.48 $217,376 - $321,048
25,725 New
25,725 $260,000

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $178M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.